In a study of several melanoma cases, Kiniwa et al. showed that the total CTC count in four of five patients with stage IV melanoma varied in response to treatment with a BRAF/MEK inhibitor, suggesting that CTC count has the potential to be used as a marker of treatment response in patients with advanced disease 5. The gene discussed is MAP2K7; the disease is melanoma.